High Lysyl Oxidase (LOX) in the Non-Malignant Prostate Epithelium Predicts a Poor Outcome in Prostate Cancer Patient Managed by Watchful Waiting

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Oct 27

PMID 26501565

Citations 12

Authors

Maria Nilsson

Christina Hagglof

Peter Hammarsten

Elin Thysell

Par Stattin

Lars Egevad

Torvald Granfors

Emma Jernberg

Pernilla Wikstrom

Sofia Halin Bergstrom

Anders Bergh

Affiliations

Soon will be listed here.

Abstract

Lysyl oxidase (LOX) has been shown to both promote and suppress tumor progression, but its role in prostate cancer is largely unknown. LOX immunoreactivity was scored in prostate tumor epithelium, tumor stroma and in the tumor-adjacent non-malignant prostate epithelium and stroma. LOX scores in tumor and non-malignant prostate tissues were then examined for possible associations with clinical characteristics and survival in a historical cohort of men that were diagnosed with prostate cancer at transurethral resection and followed by watchful waiting. Men with a low LOX score in the non-malignant prostate epithelium had significantly longer cancer specific survival than men with a high score. Furthermore, LOX score in non-malignant prostate epithelium remained prognostic in a multivariable analysis including Gleason score. LOX score in prostate tumor epithelium positively correlated to Gleason score and metastases but was not associated with cancer survival. LOX score in tumor and non-malignant prostate stroma appeared unrelated to these tumor characteristics. In radical prostatectomy specimens, LOX immune-staining corresponded to LOX in-situ hybridization and LOX mRNA levels were found to be similar between tumor and adjacent non-malignant areas, but significantly increased in bone metastases samples. LOX levels both in tumors and in the surrounding tumor-bearing organ are apparently related to prostate cancer aggressiveness.

Citing Articles

The Potential of Extracellular Matrix- and Integrin Adhesion Complex-Related Molecules for Prostate Cancer Biomarker Discovery.

Samarzija I Biomedicines. 2024; 12(1).

PMID: 38255186 PMC: 10813710. DOI: 10.3390/biomedicines12010079.

Rat prostate tumors induce DNA synthesis in remote organs.

Bergstrom S, Lundholm M, Nordstrand A, Bergh A Sci Rep. 2022; 12(1):7908.

PMID: 35551231 PMC: 9098422. DOI: 10.1038/s41598-022-12131-6.

Downregulation of LOX promotes castration-resistant prostate cancer progression via IGFBP3.

Chen X, Shao Y, Wei W, Shen H, Li Y, Chen Y J Cancer. 2022; 12(24):7349-7357.

PMID: 35003355 PMC: 8734407. DOI: 10.7150/jca.61131.

Causal contributors to tissue stiffness and clinical relevance in urology.

Martinez-Vidal L, Murdica V, Venegoni C, Pederzoli F, Bandini M, Necchi A Commun Biol. 2021; 4(1):1011.

PMID: 34446834 PMC: 8390675. DOI: 10.1038/s42003-021-02539-7.

The prognostic value of the lysyl oxidase family in ovarian cancer.

Ye M, Zhou J, Gao Y, Pan S, Zhu X J Clin Lab Anal. 2020; 34(12):e23538.

PMID: 33058284 PMC: 7755792. DOI: 10.1002/jcla.23538.

References

Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J . Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol. 2010; 177(2):1031-41. PMC: 2913352. DOI: 10.2353/ajpath.2010.100070. View

Denko N, Fontana L, Hudson K, Sutphin P, Raychaudhuri S, Altman R . Investigating hypoxic tumor physiology through gene expression patterns. Oncogene. 2003; 22(37):5907-14. DOI: 10.1038/sj.onc.1206703. View

da Silva R, Uno M, Nagahashi Marie S, Oba-Shinjo S . LOX expression and functional analysis in astrocytomas and impact of IDH1 mutation. PLoS One. 2015; 10(3):e0119781. PMC: 4366168. DOI: 10.1371/journal.pone.0119781. View

Palamakumbura A, Jeay S, Guo Y, Pischon N, Sommer P, Sonenshein G . The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem. 2004; 279(39):40593-600. DOI: 10.1074/jbc.M406639200. View

El-Haibi C, Bell G, Zhang J, Collmann A, Wood D, Scherber C . Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A. 2012; 109(43):17460-5. PMC: 3491529. DOI: 10.1073/pnas.1206653109. View

Cox T, Rumney R, Schoof E, Perryman L, Hoye A, Agrawal A . The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015; 522(7554):106-110. PMC: 4961239. DOI: 10.1038/nature14492. View

Lapointe J, Li C, Higgins J, van de Rijn M, Bair E, Montgomery K . Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004; 101(3):811-6. PMC: 321763. DOI: 10.1073/pnas.0304146101. View

Erler J, Bennewith K, Nicolau M, Dornhofer N, Kong C, Le Q . Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006; 440(7088):1222-6. DOI: 10.1038/nature04695. View

Hammarsten P, Cipriano M, Josefsson A, Stattin P, Egevad L, Granfors T . Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS One. 2012; 7(10):e47994. PMC: 3485047. DOI: 10.1371/journal.pone.0047994. View

10.

Kenyon K, Contente S, Trackman P, Tang J, Kagan H, Friedman R . Lysyl oxidase and rrg messenger RNA. Science. 1991; 253(5021):802. DOI: 10.1126/science.1678898. View

11.

Rudolfsson S, Bergh A . Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target. Expert Opin Ther Targets. 2009; 13(2):219-25. DOI: 10.1517/14728220802626249. View

12.

Ross A, Marchionni L, Vuica-Ross M, Cheadle C, Fan J, Berman D . Gene expression pathways of high grade localized prostate cancer. Prostate. 2011; 71(14):1568-77. DOI: 10.1002/pros.21373. View

13.

Halin S, Hammarsten P, Wikstrom P, Bergh A . Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. Prostate. 2006; 67(4):370-7. DOI: 10.1002/pros.20473. View

14.

Nonn L, Ananthanarayanan V, Gann P . Evidence for field cancerization of the prostate. Prostate. 2009; 69(13):1470-9. PMC: 3690597. DOI: 10.1002/pros.20983. View

15.

Zhang Q, Jin X, Yang Z, Wei M, Zhu X, Wang P . Upregulated expression of LOX is a novel independent prognostic marker of worse outcome in gastric cancer patients after curative surgery. Oncol Lett. 2013; 5(3):896-902. PMC: 3576180. DOI: 10.3892/ol.2012.1092. View

16.

Adamo H, Bergstrom S, Bergh A . Characterization of a Gene Expression Signature in Normal Rat Prostate Tissue Induced by the Presence of a Tumor Elsewhere in the Organ. PLoS One. 2015; 10(6):e0130076. PMC: 4468243. DOI: 10.1371/journal.pone.0130076. View

17.

Halin S, Hammarsten P, Adamo H, Wikstrom P, Bergh A . Tumor indicating normal tissue could be a new source of diagnostic and prognostic markers for prostate cancer. Expert Opin Med Diagn. 2013; 5(1):37-47. DOI: 10.1517/17530059.2011.540009. View

18.

Pascal L, Vencio R, Page L, Liebeskind E, Shadle C, Troisch P . Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer. 2009; 9:452. PMC: 2809079. DOI: 10.1186/1471-2407-9-452. View

19.

Halin S, Rudolfsson S, van Rooijen N, Bergh A . Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia. 2009; 11(2):177-86. PMC: 2631142. DOI: 10.1593/neo.81338. View

20.

Hammarsten P, Halin S, Wikstom P, Henriksson R, Rudolfsson S, Bergh A . Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res. 2006; 12(24):7431-6. DOI: 10.1158/1078-0432.CCR-06-1895. View